The top 5 vaccines by 2020

Pfizer's ($PFE) Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma. In fact, it's expected to widen its lead, with sales growing more than 61% over the next 5+ years; by 2020, it will be generating nearly $4 billion more than runner up Pentacel from Sanofi ($SNY), EP predicts.

As far as the rest of the list, however, EP anticipates a bit of shuffling. Merck's ($MRK) Gardasil, last year's No. 2 seller, will slide into third place to make room for Pentacel. And GlaxoSmithKline's ($GSK) Pediarix will inch up into fifth, knocking Merck's varicella jab Varivax out of the top 5.

Take a look at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013. You can also peruse the rest of EP's report by downloading it here. Questions? Comments? Let us know. -- Carly Helfand (email | Twitter)

The top 5 vaccines by 2020
Vaccine & Company
Use
2013 Sales (billions)
2020 Sales (billions)
CAGR 2013-20

Pneumococcal infection
$3.76
$6.08
7%

Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B
$1.53
$2.34
6%

Human papillomavirus (HPV)
$1.83
$2.06
2%

Influenza
$1.23
$1.82
6%

Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio
$1.35
$1.72
4%
Courtesy of EvaluatePharma

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.